Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Clinical Immunology

Symptoms and Biological Mechanisms of NFKB1

At a Glance

NFKB1-related immune dysregulation reduces a key immune-signaling protein called p50. This can weaken antibody production and disrupt other immune cells, causing recurrent infections while also increasing risks of autoimmunity, inflammation, swollen lymph nodes, and gut or lung problems.

While your previous diagnosis of Common Variable Immunodeficiency (CVID) described what was happening—low antibodies and frequent infections—the discovery of an NFKB1 pathogenic variant helps explain why. This condition is not just a simple lack of antibodies; it is a fundamental shift in how your immune system communicates and responds to the world [1][2].

The Biological Blueprint: What is p50?

To understand your diagnosis, it helps to think of the NF-κB pathway as a master control network for your immune system. This network is made of several protein “parts.” One of the most critical parts is a protein called p50, which is created from a larger precursor protein called p105 [3].

In NFKB1-related immune dysregulation, your body has one working copy of the gene and one mutated copy. This leads to haploinsufficiency, which essentially means you are short on normal functional protein [4]. Because you don’t have enough p50, the regulatory network cannot send the right signals to your cells. The signal alters regulation in complex, cell-specific ways, which can lead to both a weak defense and unwanted inflammation [5][6].

How Your Immune Cells Are Affected

Unlike some immune disorders that only affect one type of cell, NFKB1 variants impact several “branches” of your immune system.

  • B-cells (The Antibody Factory): This is the most common area of impact. In many patients, B-cells fail to mature properly. Specifically, you may have low levels of switched-memory B cells (the cells that “remember” previous infections) and an increase in CD21-low B cells [2][4]. This leads to hypogammaglobulinemia (low levels of protective antibodies like IgG, IgA, or IgM) [2].
  • T-cells (The Commanders): While many CVID patients have normal T-cells, those with NFKB1 often see changes here too. This can include low overall T-cell counts or an inverted CD4/CD8 ratio, where the balance between “helper” and “killer” T-cells is disrupted [7][8].
  • Innate Immunity (The First Responders): Your first line of defense, including cells like macrophages, can become dysregulated. Instead of quietly clearing a threat, they may release inappropriate inflammatory signals (cytokines like TNF or IL-6), contributing to chronic inflammation [9][10]. (Note: These cytokine findings are mechanistic research details and not routine tests).

Common Symptoms and Presentation

Because the immune system is affected in multiple ways, the symptoms can vary widely. However, several patterns are common. Note: These percentages come from a selected clinical cohort of 157 symptomatic patients and do not represent your individual chance of developing each problem.

Category Common Symptoms Reported Frequency (Selected Cohort)
Infections Recurrent sinus infections, pneumonia, and bronchitis. ~83% [2]
Gut Health Gastrointestinal infections. ~28.6% [2]
Autoimmunity The body attacking itself (e.g., low blood counts). ~57.4% [2]
Swelling Enlarged lymph nodes (lymphadenopathy) or an enlarged spleen (splenomegaly). ~52.4% [2]

Why This Isn’t “Generic” CVID

For a long time, NFKB1-related disease was simply called CVID. However, researchers now recognize that the NFKB1 version often has a more complex “personality” than generic CVID.

  1. More Than Antibodies: While generic CVID can include non-infectious complications, NFKB1 involves broader immune dysregulation. This means some cohorts show more “non-infectious” complications like autoimmunity, gut inflammation, or lung scarring (bronchiectasis) than someone with a different, genetically undefined form of CVID [11].
  2. Age-Related Presentation: While CVID can appear at any time, NFKB1 often shows a very clear age-dependent variability, where symptoms may be absent in childhood but become more apparent in adulthood [12][2].

Understanding these biological differences helps your medical team move from “one-size-fits-all” CVID care to an individualized strategy that monitors your specific risks.

Common questions in this guide

What does an NFKB1 pathogenic variant do to the immune system?
An NFKB1 variant can leave the body with too little functional p50, a protein that helps control immune-cell communication. This may weaken the response to infections while also causing poorly controlled inflammation in some immune cells.
Why can NFKB1-related immune dysregulation cause repeated infections?
NFKB1 changes can interfere with B-cell development and the production of protective antibodies such as IgG, IgA, and IgM. As a result, some people have repeated sinus infections, pneumonia, bronchitis, or gastrointestinal infections.
What B-cell changes might appear with NFKB1-related disease?
Testing may show fewer switched-memory B cells and more CD21-low B cells, although results vary from person to person. These changes can occur along with low levels of protective antibodies, called hypogammaglobulinemia.
Can NFKB1 affect T cells and inflammation as well as antibodies?
Yes. Some people have low T-cell counts or an altered balance between CD4 helper T cells and CD8 killer T cells. NFKB1 changes can also affect first-response immune cells and inflammatory signals, so the condition may involve more than antibody deficiency.
What noninfectious problems can occur with NFKB1-related immune dysregulation?
Possible problems include autoimmunity, low blood counts, gut inflammation or persistent digestive symptoms, enlarged lymph nodes, an enlarged spleen, and bronchiectasis. Having an NFKB1 variant does not mean a person will develop all of these complications.
Is NFKB1-related disease the same as generic CVID?
NFKB1-related disease may be recognized clinically as CVID, but the genetic cause can produce broader immune dysregulation than antibody deficiency alone. Symptoms may also be age-dependent, appearing later or becoming more noticeable in adulthood.

Get notified when new evidence is published on NFKB1-related immune dysregulation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (12)
  1. 1

    Common Variable Immunodeficiency Disorders: A perspective from New Zealand.

    Ameratunga R, J Longhurst H, Lehnert K, et al.

    Clinical reviews in allergy & immunology 2025; (68(1)):105 doi:10.1007/s12016-025-09099-2.

    PMID: 41324804
  2. 2

    Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations.

    Lorenzini T, Fliegauf M, Klammer N, et al.

    The Journal of allergy and clinical immunology 2020; (146(4)):901-911 doi:10.1016/j.jaci.2019.11.051.

    PMID: 32278790
  3. 3

    Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable Immunodeficiency.

    Fliegauf M, Bryant VL, Frede N, et al.

    American journal of human genetics 2015; (97(3)):389-403.

    PMID: 26279205
  4. 4

    Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans.

    Tuijnenburg P, Lango Allen H, Burns SO, et al.

    The Journal of allergy and clinical immunology 2018; (142(4)):1285-1296 doi:10.1016/j.jaci.2018.01.039.

    PMID: 29477724
  5. 5

    Biochemically deleterious human NFKB1 variants underlie an autosomal dominant form of common variable immunodeficiency.

    Li J, Lei WT, Zhang P, et al.

    The Journal of experimental medicine 2021; (218(11)) doi:10.1084/jem.20210566.

    PMID: 34473196
  6. 6

    Clinical, genetic, and functional characterization of novel NFKB1 variants in Chinese patients with primary immunodeficiency.

    Zhang J, Cai H, Zhu T, Shen M

    Clinical and experimental immunology 2026; (220(1)) doi:10.1093/cei/uxag033.

    PMID: 42252100
  7. 7

    Clinical and immunological characterization of NFKB1 haploinsufficiency in Japan.

    Moriya K, Kamiyama Y, Ogino R, et al.

    Frontiers in immunology 2026; (17()):1866459 doi:10.3389/fimmu.2026.1866459.

    PMID: 42488646
  8. 8

    NF-κB1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation.

    Boztug H, Hirschmugl T, Holter W, et al.

    Journal of clinical immunology 2016; (36(6)):533-40 doi:10.1007/s10875-016-0306-1.

    PMID: 27338827
  9. 9

    Defining the Role of Nuclear Factor (NF)-κB p105 Subunit in Human Macrophage by Transcriptomic Analysis of NFKB1 Knockout THP1 Cells.

    Somma D, Kok FO, Kerrigan D, et al.

    Frontiers in immunology 2021; (12()):669906 doi:10.3389/fimmu.2021.669906.

    PMID: 34721373
  10. 10

    Truncating NFKB1 variants cause combined NLRP3 inflammasome activation and type I interferon signaling and predispose to necrotizing fasciitis.

    Nurmi K, Silventoinen K, Keskitalo S, et al.

    Cell reports. Medicine 2024; (5(4)):101503 doi:10.1016/j.xcrm.2024.101503.

    PMID: 38593810
  11. 11

    Common Variable Immunodeficiency Clinical Manifestations Are Shaped by Presence and Type of Heterozygous NFKB1 Variants.

    Yin J, Hayes KM, Ong MS, et al.

    The journal of allergy and clinical immunology. In practice 2025; (13(3)):639-646 doi:10.1016/j.jaip.2024.12.002.

    PMID: 39672378
  12. 12

    Vulnerability to Meningococcal Disease in Immunodeficiency Due to a Novel Pathogenic Missense Variant in NFKB1.

    Anim M, Sogkas G, Schmidt G, et al.

    Frontiers in immunology 2021; (12()):767188 doi:10.3389/fimmu.2021.767188.

    PMID: 35003082

This page is for informational purposes only and does not constitute medical advice. Ask your immunology or genetics team to interpret your NFKB1 variant, test results, and personal risks.